GAINESVILLE, Fla.--(BUSINESS WIRE)-- IrriMax Corporation announced today that it has been awarded a three-year contract from Novation, the healthcare industry’s leading supply contracting company. Novation provides savings to members and affiliates of VHA Inc., the University HealthSystem Consortium (UHC) and Provista.
The agreement, effective July 1, 2011, offers the company’s IrriSept® Cleansing and Debridement System with Chlorhexidine Gluconate (CHG). The agreement was awarded through Novation’s competitive new technology evaluation process.
“We are very pleased to have been selected through Novation’s new technology process and are eager to provide VHA, UHC, and Provista members an alternative to saline irrigation with IrriSept, the first and only FDA-cleared cleansing and debridement system containing CHG,” explains Gareth Clarke, chief executive officer of IrriMax. “The two companies are looking forward to their new partnership.”
“The 0.05 percent CHG concentration in IrriSept has been shown effective in laboratory testing against a variety of bacteria and fungi, including Staph and MRSA,” 1,2 continues Clarke. “Our goals are to improve patient outcomes by helping resolve and/or prevent infections, and to increase the safety of medical professionals. “We believe this new product has the potential to improve patient outcomes, decrease hospital lengths of stay and help medical facilities address infection-related challenges.”
Founded in 1998, Novation is the leading health care supply contracting company for more than 25,000 members of VHA Inc. and the University HealthSystem Consortium (UHC), two national health care alliances, and 5,500 members of Provista, LLC, representing more than 30,000 sites. Novation provides alliance members sourcing and information and data services. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 600 suppliers. VHA, UHC and Provista members used Novation contracts to purchase nearly $40 billion in 2010.
About IrriMax Corporation
Founded in 2003, IrriMax Corporation develops and markets irrigation solutions using a patented, innovative delivery method that produces unmatched efficacy and safety. The medical device company’s goal is to improve patient outcomes by helping treat and prevent infections, as well as to increase the safety of healthcare workers. Its flagship product, IrriSept®, is the first and only FDA-cleared irrigation system containing CHG. Continual innovation and ongoing clinical research guide the development of IrriMax products. For more information, visit www.irrisept.com.
1 Laboratory Testing Records per USP <51>, Antimicrobial Effectiveness Testing, on file at IrriMax Corporation
2 Laboratory Testing Records, “Chlorhexidine Gluconate (CHG) Bacterial Study Report,” on file at IrriMax Corporation
For IrriMax Corporation
Debra Patterson, 404-843-8786
KEYWORDS: United States North America Florida
INDUSTRY KEYWORDS: Surgery Health Biotechnology Hospitals Infectious Diseases Medical Devices Other Health Medical Supplies Nursing Managed Care